Premium
Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies
Author(s) -
Ströhlein Michael A.,
Heiss Markus M.
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21338
Subject(s) - medicine , peritoneal carcinomatosis , gastrointestinal tract , gastrointestinal cancer , immunotherapy , cancer , antibody , peritoneum , surgery , immunology , colorectal cancer
Prognosis of peritoneal carcinomatosis (PC) from GI tract cancers remains poor. As 30% of patients develop PC after curative surgery, prevention of PC during cancer resection would be desirable. Regarding physiopathology of PC and intraperitoneal immunology, intraoperative application of trifunctional antibodies offers advanced opportunities for destruction of intraperitoneal tumor cells and prevention of PC. First results indicated, the intraoperative treatment with trifunctional antibodies was safe and clinically feasible. Long‐term results will be available in 2010. J. Surg. Oncol. 2009;100:329–330. © 2009 Wiley‐Liss, Inc.